Elizabeth Cortés-Adasme

Mrs. Elizabeth Cortés-Adasme

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Journal of Luminescence
Verified
Journal Article
Closed access
MVM. Vega
M. Vega
IMI.R. Martin
I.R. Martin
ECElizabeth Cortés-Adasme
Elizabeth Cortés-Adasme
JLJaime Llanos
Jaime Llanos

17 October 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SSSebastián Salazar Sandoval
Sebastián Salazar Sandoval
ECElizabeth Cortés-Adasme
Elizabeth Cortés-Adasme
EGEduardo Gallardo-Toledo
Eduardo Gallardo-Toledo
IAIngrid Araya
Ingrid Araya
FCFreddy Celis
Freddy Celis
MKMarcelo Kogan
Marcelo Kogan
This article describes the synthesis and characterization of two nanocarriers consisting of β-cyclodextrin-based nanosponges (NSs) inclusion compounds (ICs) and gold nanorods (AuNRs) for potential near-infrared II (NIR-II) drug-delivery systems. These nanosystems sought to improve the stability of two drugs, namely melphalan (MPH) and curcumin (CUR), and to trigger their photothermal release after a laser irradiation stimulus (1064 nm). The inclusion of MPH and CUR inside each NS was confirmed by field emission scanning electron microscopy (FE-SEM), Raman spectroscopy, Fourier transform infrared spectroscopy, (FT-IR) differential scanning calorimetry (DSC), transmission electron microscopy (TEM), and proton nuclear magnetic resonance (1H-NMR). Furthermore, the association of AuNRs with both ICs was confirmed by FE-SEM, energy-dispersive spectroscopy (EDS), TEM, dynamic light scattering (DLS), ζ-potential, and UV–Vis. Moreover, the irradiation assays demonstrated the feasibility of the controlled-photothermal drug release of both MPH and CUR in the second biological window (1000–1300 nm). Finally, MTS assays depicted that the inclusion of MPH and CUR inside the cavities of NSs reduces the effects on mitochondrial activity, as compared to that observed in the free drugs. Overall, these results suggest the use of NSs associated with AuNRs as a potential technology of controlled drug delivery in tumor therapy, since they are efficient and non-toxic materials.

25 October 2025 in Materials Today Bio
Verified
Journal Article
Open access
AAAndreas Arellano
Andreas Arellano
SPSujey Palma-Florez
Sujey Palma-Florez
PCPablo Cabrera
Pablo Cabrera
ECElizabeth Cortés-Adasme
Elizabeth Cortés-Adasme
KBKaren Bolaños
Karen Bolaños
NHNatalia Hassan
Natalia Hassan
Gold nanoparticles (GNP) are highly valuable in nanotechnology due to their biocompatibility and unique physicochemical properties, which make them attractive as nanocarriers for targeted drug delivery. In the context of neurodegenerative diseases (NDDs) such as Alzheimer's disease (AD), GNP hold promise for reducing the toxicity of Amyloid-β peptide (Aβ) aggregates. However, a major challenge in developing new therapies for NDDs lies in the limited reliance on animal models and the difficulty of crossing the blood-brain barrier (BBB). This study investigates the effects of GNP on Aβ toxicity using a human-based BBB-organ-on-a-chip model (BBB-oC), mimicking the 3D cellular architecture of the BBB under both normal and pathological conditions. We rationally designed a novel nanosystem functionalized with the peptide D3, which functions both as a selective Aβ toxicity inhibitor and a BBB-targeting agent. The results show that GNP can cross the BBB, reduce the Aβ-induced cytotoxicity, and promote the maintenance of the BBB integrity. Moreover, controlling the shape of GNP further enhanced their protective effect. Overall, this work highlights the feasibility of rationally designed GNP as a promising therapeutic strategy for AD, evaluated through a more reliable and predictive human-relevant model.

7 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
ECElizabeth Cortés-Adasme
Elizabeth Cortés-Adasme
JAJavier Avendaño-Godoy
Javier Avendaño-Godoy
SSSebastián Salazar Sandoval
Sebastián Salazar Sandoval
FCFreddy Celis
Freddy Celis
DCDiego Cortés-Arriagada
Diego Cortés-Arriagada
MKMarcelo Kogan
Marcelo Kogan
Gold nanostructures have emerged as promising platforms for the development of targeted therapies against Alzheimer's disease (AD) owing to their biocompatibility, chemical stability, and versatile surface functionalization. Among them, anisotropic gold nanorods (GNR) provide a unique nano–bio interface that can actively regulate the organization and biological performance of surface-bound ligands. Here, we designed PEGylated GNR functionalized with the D-enantiomeric peptide D3 (rprtrlhthrnr), a β-sheet breaker that selectively recognizes toxic amyloid-β (Aβ) oligomers. The aspect ratio of the GNR was engineered to extend their localized surface plasmon resonance into the second near-infrared (NIR-II) biological window, providing a platform with future theranostic potential. Physicochemical characterization confirmed successful peptide conjugation and high colloidal stability, while computational and spectroscopic analyses demonstrated that the GNR-PEG-D3 interface is stabilized by the synergistic contribution of covalent Au–S anchoring and distributed non-covalent interactions, preserving peptide accessibility for Aβ recognition. As a result, GNR-PEG-D3 exhibited significantly greater inhibition of Aβ fibrillization than the free peptide, redirected the aggregation pathway toward less ordered and less toxic species, and reduced β-sheet formation. Furthermore, the nanosystem exhibited biocompatibility and significantly ameliorated Aβ-induced paralysis in a Caenorhabditis elegans in vivo model of Alzheimer's disease. Overall, this study demonstrates that the anisotropic architecture of GNR acts as an active design element rather than a passive carrier, optimizing the spatial presentation of peptide D3 and the modulation of the Aβ aggregation process. These findings establish nanoparticle geometry as a key parameter for the rational design of next-generation peptide-based nanotherapeutics for AD.